Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized booster study of omicron-targeted Moderna vaccines in previously mRNA-vaccinated healthy adults
MOH_2022-07-14_011897Phase 2Completed
- Sponsor
- ד"ר גיל רגב-יוחאי
- Start
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of elasomeran, elasomeran + imelasomeran and elasomeran + davesomeran in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by ד"ר גיל רגב-יוחאי. Primary endpoint: Safety, immunogenicity, and efficacy of omicron-targeted mRNA booster vaccination. Started Jul 2022; status: completed.
02
Drugs
elasomeranelasomeran + imelasomeranelasomeran + davesomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on MOH_2022-07-14_011897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-07-14_011897.